Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

balugrastim

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

FDA panel backs Merck’s vorapaxar

On course for US approval to reduce vascular events in certain patients

- PMLiVE

FDA panel backs Chelsea’s Northera for rare disease

Committee votes in favour of treatment for low blood pressure

- PMLiVE

Another Ranbaxy plant falls foul of FDA

Indian company violates Good Manufacturing Practice

FDA releases draft social media guidance

Covers 'interactive promotional media', such as Facebook, Twitter and blogs

- PMLiVE

Merck shares jump on melanoma drug filing

MK-3475 could be approved by end of 2014

Daiichi Sankyo logo

Daiichi files new anticoagulant edoxaban in US and EU

Seeks approvals in atrial fibrillation and venous thromboembolism

- PMLiVE

Teva names Vigodman CEO and makes bid for NuPathe

Israeli pharma company confirms Jeremy Levin’s replacement

- PMLiVE

FDA approves GSK’s combo cancer treatment

US regulator backs Mekinist and Tafinlar to treat melanoma

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

- PMLiVE

FDA backs a brace of allergy immunotherapies

Merck & Co and Stallergenes win drug approvals in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links